D. Boral Capital Reiterates Buy Rating for Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock. D. Boral Capital’s price objective suggests a potential upside of 193.26% from the stock’s current price.

A number of other analysts have also issued reports on ANIX. Wall Street Zen raised Anixa Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, June 6th. Maxim Group initiated coverage on Anixa Biosciences in a report on Friday, March 21st. They set a “buy” rating and a $10.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Anixa Biosciences in a report on Tuesday, March 25th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Anixa Biosciences presently has a consensus rating of “Buy” and an average price target of $9.00.

Anixa Biosciences Trading Down 2.3%

NASDAQ ANIX opened at $3.41 on Tuesday. The stock has a 50-day moving average of $2.71 and a 200 day moving average of $2.80. Anixa Biosciences has a twelve month low of $2.07 and a twelve month high of $4.20. The stock has a market capitalization of $109.84 million, a price-to-earnings ratio of -8.74 and a beta of 0.34.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Tuesday, June 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. Equities analysts predict that Anixa Biosciences will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling at Anixa Biosciences

In other news, CEO Amit Kumar acquired 10,000 shares of the company’s stock in a transaction dated Wednesday, June 4th. The stock was acquired at an average cost of $2.85 per share, with a total value of $28,500.00. Following the completion of the purchase, the chief executive officer now owns 569,925 shares of the company’s stock, valued at $1,624,286.25. This represents a 1.79% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 25.30% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its stake in Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after acquiring an additional 3,900 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Anixa Biosciences in the 4th quarter worth approximately $67,000. LPL Financial LLC increased its holdings in Anixa Biosciences by 37.2% during the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock valued at $100,000 after acquiring an additional 11,633 shares in the last quarter. Prosperity Wealth Management Inc. acquired a new position in shares of Anixa Biosciences in the fourth quarter worth $54,000. Finally, Focus Partners Wealth acquired a new position in Anixa Biosciences in the 4th quarter valued at $162,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.